RONAPREVE

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, New Zealand, Poland, Romania, UK.

Active ingredients

The drug RONAPREVE contains a combination of these active pharmaceutical ingredients (APIs):

1	Casirivimab UNII J0FI6WE1QN - CASIRIVIMAB
2	Imdevimab UNII 2Z3DQD2JHM - IMDEVIMAB

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RONAPREVE Solution for injection/infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD07		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1864997, 1865055
FR	Base de données publique des médicaments	64086026, 67613850
IT	Agenzia del Farmaco	049766013, 049766025
JP	医薬品医療機器総合機構	62505A0A1031, 62505A0A2038
LT	Valstybinė vaistų kontrolės tarnyba	1093629, 1093630
NZ	Medicines and Medical Devices Safety Authority	22691
PL	Rejestru Produktów Leczniczych	100459990
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68264001, W68265001